Nominations are invited to fill a vacancy on Board of Directors of Harm Reduction International. This vacancy is to fill the seat on the Board reserved for a representative of people who use drugs. The appointment will be for a three-year term, with possible renewal.

Harm Reduction International is a UK company registered under Company Law in England and Wales, and also a Charity registered in England and Wales. Therefore, the person elected will be both a Director of the Company and a Trustee of the Charity.

The Board of Directors is responsible for the governance of the organisation and the broad strategy. They have ultimate responsibility for directing the affairs of Harm Reduction International, ensuring that it is well-run and delivering the charitable outcomes for the benefit of the public for which it was set up.

Meeting twice annually, the Board is responsible for ensuring that Harm Reduction International:

  • Meets its legal and financial obligations
  • Has a clear set of goals or strategy
  • Undertakes actions to achieve those goals
  • Uses it resources only to further its charitable purposes

Meetings of the Directors, and all documentation and communication, are in English.

Directors must to be available for two two-day face-to-face meetings each year in London (travel and accommodations paid for by HRI).  The successful applicant must be willing to attend the next HRI Board meeting taking place July 2017.

Good telephone and internet access is essential. Directors are also expected to be available to provide advice and comments between meetings.

Click here to view Harm Reduction International Governance section of the website – including the ‘Memorandum of Understanding’ (our rules and regulations).

Interested candidates are asked to submit:

  1.  a short (250 word) profile or statement of interest, and a CV (optional)
  2. a letter of support from a drug user network or organisation

Please submit the above to rick.lines@hri.globalThe closing date for nominations is 5pm GMT on 30 April 2017.